Background: Mandibular advancement devices (MADs) are considered an effective therapeutic option for managing obstructive sleep apnea syndrome (OSAS) in adults. Obstructive sleep apnea (OSA) is associated with a range of comorbidities, notably cardiovascular disease. The aim of the present retrospective study is to evaluate respiratory and cardiovascular parameters in OSA patients treated with a MAD. Methods: A total of 64 adults with OSA from moderate-to-severe OSAS underwent split-night polysomnography (SN-PSG) at baseline (T0) and after three months of treatment with a MAD (T1) and were subsequently analyzed using statistical methods for a comparative evaluation. Results: After 3 months of treatment, patients showed a significant decrease in mean heart rate (p < 0.05), maximum heart rate (p < 0.01) and in both the AHI and ODI (p < 0.01), along with a significant increase in minimum heart rate (p < 0.05).Conclusions: These findings indicate that MAD therapy may contribute to improvements in both respiratory efficiency and cardiovascular function in individuals with OSAS, offering a valuable integrated treatment strategy for patients with coexisting cardiovascular conditions.
Effects of Mandibular Advancement Device on Cardiovascular and Respiratory Parameters in OSA Patients
Ciavarella, Domenico;Ferrara, Donatella;Fanelli, Carlotta;Esperouz, Fariba;Burlon, Giuseppe;Lo Russo, Lucio;Tepedino, Michele;Lorusso, Mauro
2025-01-01
Abstract
Background: Mandibular advancement devices (MADs) are considered an effective therapeutic option for managing obstructive sleep apnea syndrome (OSAS) in adults. Obstructive sleep apnea (OSA) is associated with a range of comorbidities, notably cardiovascular disease. The aim of the present retrospective study is to evaluate respiratory and cardiovascular parameters in OSA patients treated with a MAD. Methods: A total of 64 adults with OSA from moderate-to-severe OSAS underwent split-night polysomnography (SN-PSG) at baseline (T0) and after three months of treatment with a MAD (T1) and were subsequently analyzed using statistical methods for a comparative evaluation. Results: After 3 months of treatment, patients showed a significant decrease in mean heart rate (p < 0.05), maximum heart rate (p < 0.01) and in both the AHI and ODI (p < 0.01), along with a significant increase in minimum heart rate (p < 0.05).Conclusions: These findings indicate that MAD therapy may contribute to improvements in both respiratory efficiency and cardiovascular function in individuals with OSAS, offering a valuable integrated treatment strategy for patients with coexisting cardiovascular conditions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


